Published in Cancer Weekly, October 23rd, 2007
"However, the clinical development of I3C has been impeded by its poor metabolic profile. The active components of I3C were used to develop a novel class of indole analogs to optimize I3C's anticancer actions, including blocking growth factor-stimulated Akt activation," wrote W.R. Chao and colleagues.
The researchers concluded: "The most promising of these analogs, SR13668, exhibited potent oral anticancer activity against various cancers and no significant toxicity."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.